269 related articles for article (PubMed ID: 25630650)
1. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.
Duraffour S; Lorenzo MM; Zöller G; Topalis D; Grosenbach D; Hruby DE; Andrei G; Blasco R; Meyer H; Snoeck R
J Antimicrob Chemother; 2015 May; 70(5):1367-80. PubMed ID: 25630650
[TBL] [Abstract][Full Text] [Related]
2. Specific targeting of the F13L protein by ST-246 affects orthopoxvirus production differently.
Duraffour S; Vigne S; Vermeire K; Garcel A; Vanstreels E; Daelemans D; Yang G; Jordan R; Hruby DE; Crance JM; Garin D; Andrei G; Snoeck R
Antivir Ther; 2008; 13(8):977-90. PubMed ID: 19195323
[TBL] [Abstract][Full Text] [Related]
3. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
4. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.
Duraffour S; Snoeck R; de Vos R; van Den Oord JJ; Crance JM; Garin D; Hruby DE; Jordan R; De Clercq E; Andrei G
Antivir Ther; 2007; 12(8):1205-16. PubMed ID: 18240860
[TBL] [Abstract][Full Text] [Related]
5. Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.
Duraffour S; Andrei G; Topalis D; Krečmerová M; Crance JM; Garin D; Snoeck R
J Virol; 2012 Jul; 86(13):7310-25. PubMed ID: 22532673
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility to ST-246 and Cidofovir corroborates the phylogenetic separation of Brazilian Vaccinia virus into two clades.
Pires MA; Rodrigues NFS; de Oliveira DB; de Assis FL; Costa GB; Kroon EG; Mota BEF
Antiviral Res; 2018 Apr; 152():36-44. PubMed ID: 29427676
[TBL] [Abstract][Full Text] [Related]
7. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
Smee DF; Sidwell RW; Kefauver D; Bray M; Huggins JW
Antimicrob Agents Chemother; 2002 May; 46(5):1329-35. PubMed ID: 11959564
[TBL] [Abstract][Full Text] [Related]
8. Vaccinia virus F13L protein with a conserved phospholipase catalytic motif induces colocalization of the B5R envelope glycoprotein in post-Golgi vesicles.
Husain M; Moss B
J Virol; 2001 Aug; 75(16):7528-42. PubMed ID: 11462025
[TBL] [Abstract][Full Text] [Related]
9. Similarities in the induction of post-Golgi vesicles by the vaccinia virus F13L protein and phospholipase D.
Husain M; Moss B
J Virol; 2002 Aug; 76(15):7777-89. PubMed ID: 12097590
[TBL] [Abstract][Full Text] [Related]
10. Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.
Roscoe F; Xu RH; Sigal LJ
J Virol; 2012 Dec; 86(24):13501-7. PubMed ID: 23035222
[TBL] [Abstract][Full Text] [Related]
11. Vaccinia Virus Phospholipase Protein F13 Promotes Rapid Entry of Extracellular Virions into Cells.
Bryk P; Brewer MG; Ward BM
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540596
[TBL] [Abstract][Full Text] [Related]
12. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®.
Santos-Fernandes É; Beltrame CO; Byrd CM; Cardwell KB; Schnellrath LC; Medaglia ML; Hruby DE; Jordan R; Damaso CR
Antiviral Res; 2013 Mar; 97(3):301-11. PubMed ID: 23257396
[TBL] [Abstract][Full Text] [Related]
13. KAY-2-41, a novel nucleoside analogue inhibitor of orthopoxviruses in vitro and in vivo.
Duraffour S; Drillien R; Haraguchi K; Balzarini J; Topalis D; van den Oord JJ; Andrei G; Snoeck R
Antimicrob Agents Chemother; 2014; 58(1):27-37. PubMed ID: 24126587
[TBL] [Abstract][Full Text] [Related]
14. Preliminary Screening and In Vitro Confirmation of Orthopoxvirus Antivirals.
Grosenbach DW; Hruby DE
Methods Mol Biol; 2019; 2023():143-155. PubMed ID: 31240676
[TBL] [Abstract][Full Text] [Related]
15. Envelope formation is blocked by mutation of a sequence related to the HKD phospholipid metabolism motif in the vaccinia virus F13L protein.
Roper RL; Moss B
J Virol; 1999 Feb; 73(2):1108-17. PubMed ID: 9882312
[TBL] [Abstract][Full Text] [Related]
16. [Research progress in the structure and fuction of Orthopoxvirus host range genes].
Liu Z; Liu Y; Shao YM
Bing Du Xue Bao; 2013 Jun; 29(4):437-41. PubMed ID: 23895011
[TBL] [Abstract][Full Text] [Related]
17. Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication.
Soares JA; Leite FG; Andrade LG; Torres AA; De Sousa LP; Barcelos LS; Teixeira MM; Ferreira PC; Kroon EG; Souto-Padrón T; Bonjardim CA
J Virol; 2009 Jul; 83(13):6883-99. PubMed ID: 19386722
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Cowpox Virus and Vaccinia Virus Mature Virion Proteome: Analysis of the Species- and Strain-Specific Proteome.
Doellinger J; Schaade L; Nitsche A
PLoS One; 2015; 10(11):e0141527. PubMed ID: 26556597
[TBL] [Abstract][Full Text] [Related]
19. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
Quenelle DC; Prichard MN; Keith KA; Hruby DE; Jordan R; Painter GR; Robertson A; Kern ER
Antimicrob Agents Chemother; 2007 Nov; 51(11):4118-24. PubMed ID: 17724153
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice.
Grosenbach DW; Berhanu A; King DS; Mosier S; Jones KF; Jordan RA; Bolken TC; Hruby DE
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):838-43. PubMed ID: 20080762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
